ADRENALIN Drug Patent Profile

When do Adrenalin patents expire, and what generic alternatives are available?

Adrenalin is a drug marketed by Ph Health and is included in three NDAs. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has nine patent family members in seven countries.

The generic ingredient in ADRENALIN is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adrenalin

A generic version of ADRENALIN was approved as epinephrine by BPI LABS on July 29^th, 2014.

Summary for ADRENALIN

International Patents:	9
US Patents:	8
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	48
Patent Applications:	4,088
Drug Prices:	Drug price information for ADRENALIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADRENALIN
What excipients (inactive ingredients) are in ADRENALIN?	ADRENALIN excipients list
DailyMed Link:	ADRENALIN at DailyMed

See drug prices for ADRENALIN

See drug sales revenues for ADRENALIN

Recent Clinical Trials for ADRENALIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ARS Pharmaceuticals, Inc.	PHASE4
Assiut University	EARLY_PHASE1
Instituto Latino Americano de Sepse	PHASE2

See all ADRENALIN clinical trials

Pharmacology for ADRENALIN

Drug Class	Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists

Paragraph IV (Patent) Challenges for ADRENALIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADRENALIN	Injection	epinephrine	30 mg/30 mL	204640	1	2018-08-20
ADRENALIN	Injection	epinephrine	1 mg/mL ampules	204200	1	2016-03-09

US Patents and Regulatory Information for ADRENALIN

ADRENALIN is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	ADRENALIN	epinephrine	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	204200-001	Dec 7, 2012	AP	RX	Yes	Yes	9,295,657
Ph Health	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-003	Apr 21, 2023		RX	Yes	Yes	12,133,837		Y
Ph Health	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-005	Apr 21, 2023		RX	Yes	Yes	11,083,698
Ph Health	ADRENALIN	epinephrine	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	204640-001	Dec 18, 2013	AP	RX	Yes	Yes	12,280,024		Y

International Patents for ADRENALIN

See the table below for patents covering ADRENALIN around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016149028
South Korea	20180034307	에피네프린 제형
Australia	2016233682	Epinephrine formulations
European Patent Office	3268045	FORMULATIONS D'ÉPINÉPHRINE (EPINEPHRINE FORMULATIONS)

Supplementary Protection Certificates for ADRENALIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	2025C/508	Belgium		PRODUCT NAME: COMBINATIE VAN EPINEPHRINE EN DODECYLMALTOSIDE, IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20240823

Market Dynamics and Financial Trajectory for ADRENALIN (Epinephrine)

Last updated: February 22, 2026

What is the current market size and segmentation for adrenaline-based products?

The global adrenaline (epinephrine) market was valued at approximately USD 800 million in 2022 and is projected to reach USD 1.2 billion by 2027, growing at a compound annual growth rate (CAGR) of 8.6%.[1] The primary segments include emergency medical supplies, allergy management, local anesthesia, and veterinary use. Emergency supplies dominate with over 60% market share, driven by high demand for anaphylaxis treatment.

How does regulatory status impact market growth?

The U.S. Food and Drug Administration (FDA) approved the first epinephrine auto-injector, EpiPen, in 1988. Since then, regulatory landscape has evolved:

• FDA approved multiple auto-injectors, including authorized generics, with regulatory renewals every 5 years.
• European Medicines Agency (EMA) approvals mirror FDA standards, facilitating market expansion across Europe.
• The expiration of patent protections shifted focus to biosimilar products; Synacthen and other generics entered markets around 2015–2018.

This landscape encourages new entrants but also stabilizes demand for established brands like Mylan's EpiPen.

What are the key driving forces and barriers?

Drivers

• Increasing prevalence of allergic conditions: The global incidence of food allergies rose from 1.2% in 2000 to 2.5% in 2022.[2]
• Growing awareness of anaphylaxis: Public health campaigns and hospital protocols have made adrenaline auto-injectors more prevalent.
• Expanding use in anesthesia and veterinary medicine: These segments are growing steadily.

Barriers

• Price sensitivity: EpiPen's pricing controversy led to increased demand for cost-effective alternatives.
• Supply chain issues: Shortages under stress from manufacturing disruptions and COVID-19 impact sales.
• Technological innovation: Development of alternative routes and formulations may impact traditional auto-injector sales.

How do patent and patent expiry influence the market?

Patent protection for original formulations and devices generally lasts 20 years from filing. EpiPen's patent expired in 2018, enabling biosimilar entries such as Teva's and other generics. This led to a reduction in price and increased competition:

Year	Patent Expiry	Market Impact	Key Products Entering Market
2018	20-year patent for EpiPen	Price decline, increased competition	Multiple generics approved by FDA
2020	Secondary patents expire	Greater biosimilar market entry	Several biosimilars launched at 30-40% lower prices

The patent landscape remains complex with patent extensions and litigation influencing the timeline.

What are the financial trajectories of key industry players?

Major players include Mylan (now part of Viatris), Teva Pharmaceutical Industries, and ALK-Abelló. Their revenues from adrenaline auto-injectors are:

Company	2022 Revenue (USD millions)	Market Share	Notes
Viatris (EpiPen)	550	70%	Dominates U.S. auto-injector market
Teva	100	12.5%	Gained share with generic auto-injectors
ALK	50	6.25%	Focus on allergy management products

Viatris reported a 5% decline in EpiPen revenue in 2022 due to increased competition but maintained high margins. Generic entrants saw margins shrink but increased overall unit sales.

What is the future outlook for the market and financial performance?

Projections suggest annual revenue growth will accelerate with innovation:

• New auto-injector designs: Needleless or more user-friendly devices under development.
• Alternate formulations: Intranasal sprays and patches in clinical trials to improve compliance.
• Geographic expansion: Growth in emerging markets—Asia-Pacific expected to grow at 10% CAGR through 2027, driven by increased healthcare spending and awareness.

Estimates indicate that leading companies will adjust their portfolios, focusing on biosystems with better dosage control and cost efficiencies.

What are the implications of patent litigation and regulatory changes?

Patent litigation remains active, with patent challenges occurring frequently during expiry periods.[3] Regulatory agencies tightening approval processes for biosimilar products could delay new entrants but also increase costs for generic manufacturers.

For example:

• FDA classifies biosimilars as interchangeable if they meet strict criteria, affecting market penetration.
• Increased regulatory scrutiny may extend time-to-market for novel formulations or devices.

Key Takeaways

• The global adrenaline market reached USD 800 million in 2022, expected to grow to USD 1.2 billion by 2027.
• Market growth driven by increased allergy prevalence, awareness, and veterinary applications.
• Patent expiry since 2018 led to increased competition and price reductions.
• Major companies maintain strong revenues, with high margins for initial auto-injectors.
• Future growth depends on device innovation, formulation improvements, regulatory environment, and geographic expansion.

FAQs

1. What factors most influence adrenaline market growth?

Prevalence of allergic diseases, regulatory approvals, healthcare infrastructure development, and innovation in delivery devices.

2. How has patent expiration affected market competition?

Patent expiry in 2018 allowed biosimilars and generics to enter, reducing prices and increasing unit sales, although price competition has pressured margins of original brands.

3. What are emerging trends in adrenaline product development?

Needleless devices, intranasal formulations, and combination therapies to improve ease of use and compliance.

4. Which regions present the greatest growth opportunities?

Asia-Pacific and Latin America, due to expanding healthcare coverage and rising awareness.

5. How might regulatory changes impact future market dynamics?

More stringent biosimilar approval processes could slow entry but enhance product safety, potentially increasing market consolidation.

---

References

[1] Markets and Markets. (2023). Epinephrine Market by Application, Route of Administration and Geography.
[2] World Allergy Organization. (2022). Global Allergy Prevalence Data.
[3] U.S. FDA. (2022). Biosimilar Application and Patent Litigation.